Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study
Standard
Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. / Köster, Ralf; Kaehler, Jan; Meinertz, Thomas; REDUCTION Study Group.
in: AM HEART J, Jahrgang 158, Nr. 4, 10.2009, S. 51-57.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study
AU - Köster, Ralf
AU - Kaehler, Jan
AU - Meinertz, Thomas
AU - REDUCTION Study Group
PY - 2009/10
Y1 - 2009/10
N2 - BACKGROUND: The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice.METHODS: In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated.RESULTS: Within 4 months of treatment with ivabradine, HR was reduced by 12.4 +/- 12.2 beat/min from 82.9 +/- 15.3 to 70.4 +/- 9.2 beat/min (P < .0001). Angina pectoris attacks were reduced from 2.4 +/- 3.1 to 0.4 +/- 1.5 per week (P < .0001). Consumption of short-acting nitrates was reduced from 3.3 +/- 4.4 to 0.6 +/- 1.6 U/wk (P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being "excellent/very good" for 97% and 98% of the patients treated.CONCLUSION: Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.
AB - BACKGROUND: The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice.METHODS: In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated.RESULTS: Within 4 months of treatment with ivabradine, HR was reduced by 12.4 +/- 12.2 beat/min from 82.9 +/- 15.3 to 70.4 +/- 9.2 beat/min (P < .0001). Angina pectoris attacks were reduced from 2.4 +/- 3.1 to 0.4 +/- 1.5 per week (P < .0001). Consumption of short-acting nitrates was reduced from 3.3 +/- 4.4 to 0.6 +/- 1.6 U/wk (P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being "excellent/very good" for 97% and 98% of the patients treated.CONCLUSION: Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.
KW - Aged
KW - Angina Pectoris/diagnosis
KW - Benzazepines/administration & dosage
KW - Cyclic Nucleotide-Gated Cation Channels
KW - Dose-Response Relationship, Drug
KW - Electrocardiography
KW - Female
KW - Follow-Up Studies
KW - Germany
KW - Heart Rate/drug effects
KW - Humans
KW - Ivabradine
KW - Male
KW - Prospective Studies
KW - Surveys and Questionnaires
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1016/j.ahj.2009.06.008
DO - 10.1016/j.ahj.2009.06.008
M3 - SCORING: Journal article
C2 - 19781403
VL - 158
SP - 51
EP - 57
JO - AM HEART J
JF - AM HEART J
SN - 0002-8703
IS - 4
ER -